Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RELIANT trial underway

This article was originally published in The Gray Sheet

Executive Summary

FDA clearance of IDE permits first 50 patients to be enrolled in U.S. trial comparing WorldHeart'sNovacor left-ventricular assist system with Thoratec's HeartMate XVE.The full trial, intended to support a PMA supplement for Novacor as a destination therapy in transplant-ineligible patients, will enroll 225 patients in up to 40 centers, pending further review by FDA. HeartMate is the only LVAD approved for destination therapy in the U.S. (1"The Gray Sheet" Nov. 10, 2003, p. 39)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT019841

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel